SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Kosan BioSciences -- KOSN

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: tuck8/10/2005 2:52:50 PM
  Read Replies (1) of 933
 
[Disorazoles, potent cytotoxic compounds that disrupt microtubule formation]

>>Gene. 2005 Aug 2; [Epub ahead of print]

The biosynthetic genes for disorazoles, potent cytotoxic compounds that disrupt microtubule formation.

Carvalho R, Reid R, Viswanathan N, Gramajo H, Julien B.

Kosan Biosciences, Inc., 3832 Bay Center Place, Hayward, CA 94545, United States.

Disorazoles are polyketides produced by the myxobacterium Sorangium cellulosum So ce12. Their mode of action is to inhibit tubulin polymerization and destabilize microtubules. Using transposon mutagenesis, two mutant strains were identified that produced no disorazoles. Sequencing the DNA flanking the insertions revealed a polyketide synthase gene cluster that would encode three polypeptides, DszA, DszB, and DszC, with DszC containing both nonribosomal peptide synthetase and polyketide synthase modules. The disorazole polyketide synthase modules lack an acyltransferase domain. Instead, a separate gene, dszD, encodes an AT protein, thus revealing that the disorazole gene cluster falls into the trans-AT Type I family of PKS enzymes.<<

Obviously very early. Only three other citations -- starting in 2001 -- for disorazole. No idea how important this is.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext